Showing results (1351-1360 of 1,423) with videos related to

Sort By:
Pageof 143
Annals of Neurology|June 14, 2000
Mitochondrial neurogastrointestinal encephalomyopathy: an autosomal recessive disorder due to thymidine phosphorylase mutationsI Nishino, A Spinazzola, A Papadimitriou, et al.
Journal of Personalized Medicine|November 24, 2020
Multi-Omics Identifies Circulating miRNA and Protein Biomarkers for Facioscapulohumeral DystrophyChristopher R Heier, Aiping Zhang, Nhu Y Nguyen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2024
Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol JRoisin M Connolly, Victoria Wang, David M Hyman, et al.
Breast (Edinburgh, Scotland)|March 6, 2025
A composite <sup>18</sup>F-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026)Maeve A Hennessy, Ashley Cimino-Mathews, Jodi M Carter, et al.
Human Mutation|February 15, 2022
Intron mutations and early transcription termination in Duchenne and Becker muscular dystrophyMegan A Waldrop, Steven A Moore, Katherine D Mathews, et al.
Nature|July 3, 1999
Characterization of the human cysteinyl leukotriene CysLT1 receptorK R Lynch, G P O'Neill, Q Liu, et al.
Journal of Medicinal Chemistry|November 21, 1998
(+)-4-[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5, 6]cyclohepta[1,2-b]- pyridin-11(R)-yl)-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamid e (SCH-66336): a very potent farnesyl protein transferase inhibitor as a novel antitumor agentF G Njoroge, A G Taveras, J Kelly, et al.
Muscle & Nerve|July 25, 2014
Outcome reliability in non-ambulatory boys/men with Duchenne muscular dystrophyAnne M Connolly, Elizabeth C Malkus, Jerry R Mendell, et al.
Current Biology : CB|February 26, 2020
Mangroves give cause for conservation optimism, for nowDaniel A Friess, Erik S Yando, Guilherme M O Abuchahla, et al.
The Lancet. Neurology|March 20, 2021
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trialJohn W Day, Richard S Finkel, Claudia A Chiriboga, et al.
Pageof 143